OmniAb Inc. Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Q2 Revenue: $13.4 million, a significant increase from $3.9 million in Q2 2025, primarily driven by higher milestone revenue.

Year-to-Date Revenue: $27.8 million, up from $8.1 million in the same period last year.

Net Loss: Reduced to $5.9 million ($0.05 per share) from $15.9 million ($0.15 per share) year-over-year.

Cash Position: Ended Q2 with $52 million, bolstered by milestone payments.

Active Partners: 110, with 425 active programs, 34 of which are in clinical trials.

Contracted Milestone Payments: Over $3 billion in potential milestone payments, with an average royalty rate of approximately 3.4%.

2Strategic Updates and Business Highlights

Technological Advancements: Continued progress in partner programs utilizing OmniAb's discovery technologies, including the successful launch of OmniUltra and OmnidAb, which are expanding market opportunities.

xPloration Platform: Sold 2 instruments during the quarter, with strong commercial interest and positive early feedback on performance.

Partnership Growth: New licenses signed with EnRosa Therapeutics and argenx, with ongoing discussions indicating a robust pipeline of potential partnerships.

Clinical Advancements: Notable progress in clinical programs, including several programs advancing to later stages of development.

3Forward Guidance and Outlook

Revenue Guidance: Increased for 2026 to a range of $32 million to $36 million, reflecting strong Q2 performance.

Operating Expense Guidance: Expected GAAP operating expenses narrowed to $84 million to $88 million, with cash operating expenses projected at $51 million to $55 million.

Cash Projection: Anticipated cash and cash equivalents at year-end to be between $37 million and $41 million.

4Bad News, Challenges, or Points of Concern

Funding Gap: Despite raised revenue guidance, there remains a projected gap of over $20 million between spending and expected revenues, raising questions about future funding strategies.

Variable Milestone Revenue: Milestone revenues can fluctuate significantly from quarter to quarter, which may impact financial stability.

Market Conditions: Although the funding environment for biotech has improved, there is uncertainty regarding how quickly this will translate into increased revenues for OmniAb.

5Notable Q&A Insights

xPloration Utilization: Management expressed optimism about the xPloration platform's potential to generate diverse revenue streams, though they noted it is early to assess consumables revenue.

Funding Environment: The company has seen growth in partners and programs, indicating a positive trend, but there is a recognition that the funding environment may take time to fully benefit OmniAb.

Long-Term Model: Management believes the business model will accelerate over time with increased visibility on royalties as clinical programs advance, enhancing revenue potential.

Clinical Pipeline Growth: There is confidence in the progression of programs from discovery to clinical stages, with expectations for more entrants into clinical trials in the coming months. This summary encapsulates the key points from the earnings call, providing a balanced view of OmniAb's current performance, strategic direction, and future outlook.